Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Feb;128(3):451-458.
doi: 10.1038/s41416-022-02119-4. Epub 2022 Dec 23.

Tumour-infiltrating lymphocytes: from prognosis to treatment selection

Koen Brummel #  1 , Anneke L Eerkens #  1 , Marco de Bruyn  1 , Hans W Nijman  2
Affiliations
Meta-Analysis

Tumour-infiltrating lymphocytes: from prognosis to treatment selection

Koen Brummel et al. Br J Cancer. 2023 Feb.

Abstract

Tumour-infiltrating lymphocytes (TILs) are considered crucial in anti-tumour immunity. Accordingly, the presence of TILs contains prognostic and predictive value. In 2011, we performed a systematic review and meta-analysis on the prognostic value of TILs across cancer types. Since then, the advent of immune checkpoint blockade (ICB) has renewed interest in the analysis of TILs. In this review, we first describe how our understanding of the prognostic value of TIL has changed over the last decade. New insights on novel TIL subsets are discussed and give a broader view on the prognostic effect of TILs in cancer. Apart from prognostic value, evidence on the predictive significance of TILs in the immune therapy era are discussed, as well as new techniques, such as machine learning that strive to incorporate these predictive capacities within clinical trials.

PubMed Disclaimer

Conflict of interest statement

Authors HWN and MdB hold a patent on antibodies targeting CD103 (no 62/704,258).

Comment in

References

    1. Fridman WH, Pagès F, Saut̀s-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298–306. - PubMed
    1. Zhang L, Conejo-Garcia JR, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203–13. - PubMed
    1. Maibach F, Sadozai H, Seyed Jafari SM, Hunger RE, Schenk M. Tumor-infiltrating lymphocytes and their prognostic value in cutaneous melanoma. Front Immunol. 2020;11:1–20. - PMC - PubMed
    1. Gooden MJM, De Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105:93–103. - PMC - PubMed
    1. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–4. - PubMed